Local Consolidative Therapy in Lung Cancer

26 Mar 20264 min read0 viewsJournal Feed

GIST

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic lung cancer and which patients might be considered for this treatment.

Clinical Editorial

Summary

JAMA Oncology published a clinical update in Oncology on 26 Mar 2026.

The item focuses on Local Consolidative Therapy in Lung Cancer.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

JAMA OncRelated by Conditionlung cancer

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Oncology • 14 May 2026

NatureRelated by Conditionlung cancer

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

ClinicalTrialsRelated by Conditionlung cancer

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Oncology • 14 Apr 2026

ClinicalTrialsRelated by Conditionlung cancer

FAP-targeted PET/NIR in Lung Malignant Tumors

Oncology • 01 Apr 2026

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial

Oncology • 23 Apr 2026

Feed Metadata

Source

JAMA Oncology